idc btig estim compani document
million except per share amount
slowdown sight impress leverag strong busi
true out-performance fashion sale
result best pre-announce level vs prelim
discuss public commentari last month remark y/i oper leverag
result larg beat non-gaap ep vs consensu
out-performance mean reiter revenu guidanc rang
y/i look achiev us guidanc includ
price headwind relat shift toward lower-pr sell
channel competit growth core busi remain
robust new patient still come larg mdi popul
like other surpris learn net activ patient
world-wide consid long list catalyst layer onto
core busi continu medicar adopt access
awar intens patient partner launch autom insulin
intern adopt think investor expect make year
strong beats-and-rais heighten expect mind
share trade ntm ev/sal estim thursday aftermarket
remain neutral base valuat
full roll-out still time commentari previous point
limit launch late remain goal manag
emphas focu trial regulatori file manufactur capac
continu await detail timelin launch plan ad
meaning revenu model admit forecast like
what ahead stand benefit partnership
tandem rate neutral autom insulin
deliveri launch continu transit medicar patient
increas access intens patient popul plan invest
dtc advertis launch intern market includ
japan south korea
posit outlook oper margin larg y/i increas non-gaap
oper margin make guidanc
non-gaap oper margin look achiev us ahead
schedul leverag effort optimist commentari left room
signific improv year ahead
strong sale come manufactur scale-up compani plan doubl
capac priorit readi manufactur
eye intern site third manufactur facil futur
valuat rate neutral believ current multipl
estim ntm ev/sal expens given potenti price
pressur face increas competit valuat seem
support mani investor risk discuss
believ time cgm primari method monitor glucos insulin-depend
commentari competit emphas posit impact term referr volum potenti new
patient feel investor expect extrem high come quarter concern
competit new technolog and/or increas spend
competit announc launch
continu robust adopt
acceler adopt
faster shift toward pharmaci channel greater volum uplift far outweigh
continu stabil possibl favor price environ
slowdown adopt
visibl impact cgm competit
drop price due competit reimburs
medic devic
compani dedic improv
live diabet cgm
asid creat
system compani
entrench diabet
manag ecosystem stand
benefit innov
develop intern extern
high qualiti open
partnership research
hacker pump compani
continu trend surpass street expect beat revenu estim anoth quarter
disciplin sg spend part help lower opex lead larg beat ebit non- vs
note model updat public commentari januari oper leverag oper
leverag propel signific bottom line out-performance non-gaap ep cent better
updat model sale beat updat guidanc also adjust revenu build new
inform net activ patient prior model significantli underestim number patient adjust
revenu segment model top end guidanc rang
 restat histor oper expens level prior model built opex updat
order make non-gaap opex forecast go forward easier compar y/i basi reduc gross margin
increas oper margin go forward reflect guidanc commentari around manufactur capac sg
leverag model line guidanc gm non-gaap ebit margin non-gaap adjust ebitda
non-gaap ep forecast increas result higher revenu margin adjust admit interest/oth
expens tax expens difficult forecast
actualsbtig estimate variancetot revenu net incom spend spend opex spend btig estim compani file btig ebit ebit margin actual ebit ebit margin non-vari
rate neutral believ current multipl estim ntm ev/sal expens given
potenti price pressur face increas competit valuat seem support mani
investor risk rate includ competit increas spend chang revenu growth rate fda product
recal reimburs price pressur
exhibit comp tabl large-cap peer
bpsebit bp btig estim compani file old ebit ebit margin new ebit ebit margin non-newold changentm inc ingnnot sciencesexasbuy surgicalisrgneutr entxentneutr medicalwmginot factset data btig estimatespr ptpricemarket cap bev/salescagrev/gross profit
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
